Trial Profile
Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery with Cardio-Pulmonary Bypass.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2023
Price :
$35
*
At a glance
- Drugs Pexelizumab (Primary)
- Indications Coronary disorders; Myocardial infarction
- Focus Registrational; Therapeutic Use
- Acronyms PRIMO-CABG
- Sponsors Alexion AstraZeneca Rare Disease
- 22 Sep 2009 New trial record